Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nurix Therapeutics Inc shares valued at $40,054 were sold by van Houte Hans on Oct 30 ’25. At $12.80 per share, van Houte Hans sold 3,130 shares. The insider’s holdings dropped to 43,876 shares worth approximately $0.56 million following the completion of this transaction.
Also, Ring Christine sold 3,644 shares, netting a total of over 46,631 in proceeds. Following the sale of shares at $12.80 each, the insider now holds 50,897 shares.
Before that, Hansen Gwenn had sold 4,087 shares from its account. In a trade valued at $52,300, the Chief Scientific Officer traded Nurix Therapeutics Inc shares for $12.80 each. Upon closing the transaction, the insider’s holdings decreased to 4,087 shares, worth approximately $0.98 million.
As published in their initiating research note from Mizuho on October 21, 2025, Nurix Therapeutics Inc [NRIX] has been an Outperform and the price target has been revised to $24. Analysts at Leerink Partners started covering the stock with ‘”a Market perform”‘ outlook in a report released in mid March. As of December 10, 2024, BTIG Research has initiated its “Buy” rating for NRIX. Earlier on December 06, 2024, BMO Capital Markets initiated its rating. Their recommendation was “an Outperform” for NRIX stock.
Analyzing NRIX Stock Performance
On last trading session, Nurix Therapeutics Inc [NASDAQ: NRIX] rose 9.23% to $12.78. The stock’s lowest price that day was $11.575, but it reached a high of $13.235 in the same session. During the last five days, there has been a surge of approximately 22.88%. Over the course of the year, Nurix Therapeutics Inc shares have dropped approximately -51.68%. Shares of the company reached a 52-week high of $20.66 on 01/27/25 and a 52-week low of $8.18 on 04/10/25.
Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)
According to the 24-hour chart, there is a support level at 11.77, which, if violated, would cause prices to drop to 10.77. In the upper region, resistance lies at 13.51. The next price resistance is at 14.24. RSI (Relative Strength Index) is 70.42 on the 14-day chart, showing overbought technical sentiment.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 0.82 million shares to 13.87 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 13.05 million shares. A jump of 5.93% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.69 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.69.
Which companies own the most shares of Nurix Therapeutics Inc (NRIX)?
In terms of Nurix Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, up nearly 139.32% from the previous closing price of $11.7. Analysts anticipate Nurix Therapeutics Inc stock to reach 33 by 2025, with the lowest price target being 16. In spite of this, 16 analysts ranked Nurix Therapeutics Inc stock as Buy at the end of 2025. On October 24, 2024, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
